3 active not recruiting, 3 not yet recruiting, 3 recruiting, 2 completed. 15 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Active not recruiting 3, Not yet recruiting 3, Recruiting 3, Completed 2, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow telitacicept: new trials by email Literature Review of telitacicept trials Research Report on telitacicept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease Telitacicept, Placebo - CTD-ILD | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 260 | 2026-04-20 | 2026-04-09 |
| Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease Telitacicept, Placebo - Primary Sjogren's Disease | Phase 3 | Recruiting | Vor Biopharma | 250 | 2026-02-26 | 2026-10-19 |
| TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) Telitacicept 240mg - Inflammatory Myopathy | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 30 | 2026-02-02 | 2026-01-21 |
| A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) Telitacicept, Placebo - Myasthenia Gravis, Ocular | Phase 3 | Recruiting | RemeGen Co., Ltd. | 120 | 2026-01-13 | 2026-04-09 |
| Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis Telitacicept - IgA Nephropathy (IgAN), IgAVN | Phase 3 | Not yet recruiting | Guixia Ding | 124 | 2025-08-01 | 2025-07-10 |
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) Telitacicept, Placebo - Systemic Lupus Erythematosus | Phase 3 | Withdrawn | Vor Biopharma | 2024-09-01 | 2026-01-09 | |
| To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist - IgA Nephropathy (IgAN) | Phase 3 | Active not recruiting | The Affiliated Hospital of Xuzhou Medical University | 150 | 2024-08-01 | 2025-08-01 |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) Telitacicept, Placebo - Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | Vor Biopharma | 191 | 2024-07-17 | 2026-10-15 |
| Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome Telitacicept - Nephrotic Syndrome in Children, Telitacicept | Phase 3 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 20 | 2023-11-28 | 2024-08-21 |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) Telitacicept, Placebo - Primary IgA Nephropathy | Phase 3 | Active not recruiting | RemeGen Co., Ltd. | 318 | 2023-04-28 | 2025-12-16 |
| A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome Telitacicept 80 mg, Telitacicept 160 mg, Placebo - Primary Sjogren's Syndrome | Phase 3 | Completed | RemeGen Co., Ltd. | 381 | 2023-04-06 | 2025-10-01 |
| Study of Telitacicept in Generalized Myasthenia Gravis Telitacicept, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Completed | RemeGen Co., Ltd. | 114 | 2023-03-28 | 2025-05-23 |
| Study of Telitacicept in Patients With Refractory IgA Nephropathy Telitacicept - IgA Nephropathy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2023-03-01 | 2023-02-24 |
| Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus Telitacicept, Interleukin-2 - Systemic Lupus Erythematosus | Phase 3 | Unknown | Liu Tian | 60 | 2023-02-07 | 2024-04-03 |
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) Telitacicept, Placebo - Systemic Lupus Erythematosus | Phase 3 | Terminated | Vor Biopharma | 91 | 2022-06-20 | 2026-01-09 |
Glomerulonephritis, IGA (4) · Lupus Erythematosus, Systemic (3) · Myasthenia Gravis (3) · Autoimmune Diseases (2) · Immune System Diseases (1) · Muscle Weakness (1) · Myositis (1) · Nephrotic Syndrome (1) · Sjogren's Syndrome (1)
RemeGen Co., Ltd. (5) · Vor Biopharma (4) · Guixia Ding (1) · Liu Tian (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The Children's Hospital of Zhejiang University School of Medicine (1) · Zhongming Qiu (1)
China (10) · United States (4) · Argentina (2) · Australia (2) · Bulgaria (2) · Georgia (2) · Poland (2) · Spain (2) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Czechia (1) · France (1)
Jianhua Mao, MD (1) · Jicheng Lv, M.D. (1) · Zhanguo Li (1)